Ontario Regulator Pursues Multi-Million Penalties Over B.C. Biotech Share Sales
The Ontario Securities Commission (OSC) is pursuing significant penalties against Robert Freeman, a businessman from Thorndale, Ontario. The regulatory body has completed its investigation into allegations that Freeman breached securities laws while selling shares in a British Columbia biotechnology firm, Qu Biologics Inc. (QBI).
Allegations Against Robert Freeman
According to OSC documents, Freeman, 72, is accused of “perpetuating a fraud” during his transactions. The OSC claims he sold $4.8 million worth of QBI shares between 2009 and 2024 to 190 investors. The funds were allegedly transferred into his company, Plover Mills Farms Inc.
- Freeman allegedly misrepresented that his shares could be transferred to buyers while still being held in trust.
- The OSC asserts that he lacked board approval to sell his shares legally.
- The filing describes how Freeman presented himself as acting on behalf of other shareholders.
- Freeman is accused of not properly qualifying investors by failing to provide a necessary prospectus.
Background on Robert Freeman
Freeman is a notable entrepreneur who founded London Telecom in 1988, selling it for $76 million in 1999. Following this, he built a large mansion known as Avalon along the Thames River. He later battled non-Hodgkin’s lymphoma, a struggle that influenced his investment in QBI, a company specializing in immunotherapy.
Regulatory Actions and Hearings
As a result of the OSC’s findings, Freeman is currently barred from trading securities. The Capital Markets Commission held a preliminary hearing on February 9, where Freeman argued his case. He claims the OSC has misconstrued his actions and maintains that he operated transparently with investors. Freeman has enlisted legal representation to challenge the allegations.
Legal Framework and Potential Consequences
- The OSC can impose fines, penalties, and court costs up to $5 million for each breach of securities regulations.
- The tribunal may also mandate Freeman to reimburse investors and prevent him from participating in future securities trading.
The OSC will conduct a case management conference scheduled for June, marking the next step in the hearing process. The outcome will significantly influence Freeman’s business endeavors and reputation in the industry.
Qu Biologics’ Response
Qu Biologics’ management has distanced itself from Freeman, emphasizing that he has not actively participated in the company for over a decade. They confirmed that the board did not authorize any sales to non-accredited investors. This statement reinforces the regulatory body’s stance and underlines the gravity of the allegations against Freeman.
Freeman’s situation serves as a reminder of the importance of compliance with securities regulations and the consequences of alleged violations in the financial sector.
